Company: RNGE
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001641172-25-001343
Chunk: 624

Company: RANGE IMPACT, INC.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 6
Chunk 624
---
     (848,188) 
     8,458,605 

    Net increase (decrease) in cash and cash equivalents 
     (2,009,514) 
     1,734,431 
  
    Cash and cash equivalents
    - beginning of period 
     2,176,800  
     442,369 

    Cash and cash equivalents
    - end of period 
    $167,286  
    $2,176,800 

    Supplemental disclosure of cash flow information: 

    Cash paid during the period for: 

    Interest 
    $486,515  
    $506,424 
  
    Income taxes 
    $77,368  
    $- 

    Supplemental schedule of non-cash investing
    and financing activities: 

    Debt forgiveness related to asset surrender
    to CNH Capital 
    $1,012,375  
    $- 
  
    Debt forgiveness related
    to Collins Building asset disposal 
    $2,940,836  
    $- 

The
accompanying notes are an integral part of these consolidated financial statements.

F-6

RANGE
IMPACT, INC.

NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS

ENDED
DECEMBER 31, 2024 AND 2023

1.
BUSINESS OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Range
Impact, Inc. (the “Company”, “we”, “us” or “our”), was incorporated in the State of Nevada
on June 29, 2007.

Originally
founded in 2007 as Legend Mining Inc., the Company began operations as a mineral extraction exploration business. In 2011, the Company
changed its name to Stevia First Corp. and pursued a new strategy focused on developing stevia-based additives for the food and beverage
industry. In 2015, the Company changed its name to Vitality Biopharma, Inc. and pursued a new strategy focused on developing cannabinoid-based
prodrugs anticipated to treat inflammatory conditions of the gastrointestinal tract.

In
October 2021, the Company changed its name to Malachite Innovations, Inc. and formed two wholly-owned operating subsidiaries: (i) Graphium
Biosciences, Inc., a Nevada corporation (“Graphium”), into which the Company contributed all of its drug development assets;